CLINUVEL PHARMACEUTICALS LIMITED - Announcements

0.16%

$12.22

Market Cap $612.5M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on... Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

CUV	CLINUVEL Regulatory Update	PRICE SENSITIVE	14/05/18	97.21KB	Share
CUV	CLINUVEL TO TAKE 100% OWNERSHIP OF VALLAURIX JOINT VENTURE	PRICE SENSITIVE	01/05/18	558.83KB	Share
CUV	Change in substantial holding		01/05/18	516.26KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	794.86KB	Share
CUV	CLINUVEL Newsletter		28/03/18	653.85KB	Share
CUV	CLINUVEL hosts European EPP Expert Meeting	PRICE SENSITIVE	19/03/18	454.21KB	Share
CUV	CLINUVEL sustains profitability first-half of year		28/02/18	449.58KB	Share
CUV	Appendix 4D Half Yearly Report	PRICE SENSITIVE	28/02/18	476.86KB	Share
CUV	CLINUVEL unveils new global positioning		20/02/18	711.49KB	Share
CUV	CLINUVEL Newsletter		13/02/18	577.5KB	Share
CUV	Initial Director's Interest Notice		31/01/18	338.87KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/18	938.05KB	Share
CUV	CLINUVEL appoints US-based Director		29/01/18	359.71KB	Share
CUV	Chair Letter to Shareholders		11/01/18	357.85KB	Share
CUV	CLINUVEL Newsletter		21/12/17	552.75KB	Share
CUV	Preliminary assessment received from NICE	PRICE SENSITIVE	21/12/17	446.69KB	Share
CUV	CLINUVEL Newsletter		07/12/17	568.35KB	Share
CUV	Lapse and Forfeit of Unlisted Conditional Performance Rights		05/12/17	431.24KB	Share
CUV	Final Director's Interest Notice		05/12/17	338.24KB	Share
CUV	Results of Meeting		28/11/17	155.5KB	Share
CUV	Managing Director AGM Presentation		28/11/17	2.81MB	Share
CUV	Chairman's Address to Shareholders		28/11/17	508.55KB	Share
CUV	Response to ASX Price Query	PRICE SENSITIVE	07/11/17	1.02MB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/17	953.72KB	Share
CUV	Appendix 4G and Corporate Governance Statement		27/10/17	1.05MB	Share
CUV	Annual Report to shareholders		27/10/17	1.66MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		27/10/17	501.21KB	Share
CUV	CLINUVEL Newsletter		17/10/17	656.87KB	Share
CUV	AGM Date		10/10/17	425.27KB	Share
CUV	Non-Executive Director Retirement		04/10/17	432.4KB	Share
CUV	CLINUVEL provides update on SCENESSE FDA filing	PRICE SENSITIVE	19/09/17	553.42KB	Share
CUV	Appendix 3B		06/09/17	628.64KB	Share
CUV	Preliminary Final Report	PRICE SENSITIVE	30/08/17	1.01MB	Share
CUV	Change in substantial holding (Lagoda Investment Management)		09/08/17	2.07MB	Share
CUV	Amended Appendix 4C - quarterly	PRICE SENSITIVE	31/07/17	931.69KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/17	929.88KB	Share
CUV	CLINUVEL Newsletter		25/07/17	477.75KB	Share
CUV	Appendix 3B		10/05/17	628.38KB	Share
CUV	CLINUVEL Newsletter		10/05/17	573.79KB	Share
CUV	NICE England Update on SCENESSE	PRICE SENSITIVE	02/05/17	544.1KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/17	808.16KB	Share
CUV	Lapse and Forfeit of Unlisted Conditional Performance Rights		12/04/17	425.01KB	Share
CUV	CLINUVEL reaches agreement on German SCENESSE pricing	PRICE SENSITIVE	12/04/17	563.42KB	Share
CUV	Appendix 4D Half Yearly Report	PRICE SENSITIVE	24/02/17	479.08KB	Share
CUV	CLINUVEL Newsletter		16/02/17	500.41KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/17	341.5KB	Share
CUV	Change of Director's Interest Notice		23/12/16	669.31KB	Share
CUV	CLINUVEL Newsletter		20/12/16	771.68KB	Share
CUV	Change of Director's Interest Notice		13/12/16	669.06KB	Share
CUV	Results of Meeting		28/11/16	100.4KB	Share
CUV	Managing Director AGM Presentation		28/11/16	1.82MB	Share
CUV	Chairman's Address to Shareholders		28/11/16	97.65KB	Share
CUV	CLINUVEL agrees with FDA on New Drug Application timelines	PRICE SENSITIVE	09/11/16	538.02KB	Share
CUV	Response to ASX Price Query-CUV.AX	PRICE SENSITIVE	31/10/16	1002.55KB	Share
CUV	Appendix 4C - quarterly-CUV.AX	PRICE SENSITIVE	31/10/16	343.77KB	Share
CUV	Annual Report to shareholders-CUV.AX		27/10/16	1.44MB	Share
CUV	Appendix 4G and Corporate Governance Statement-CUV.AX		27/10/16	1011.26KB	Share
CUV	Notice of Annual General Meeting/Proxy Form-CUV.AX		27/10/16	453.62KB	Share
CUV	CLINUVEL Relocates Melbourne Office-CUV.AX		24/10/16	328.66KB	Share
CUV	FDA erythropoietic protoporphyria (EPP) scientific workshop-CUV.AX		24/10/16	336.8KB	Share
CUV	SCENESSE - NICE England Update-CUV.AX	PRICE SENSITIVE	18/10/16	284.96KB	Share
CUV	Media Release-CLINUVEL to discuss SCENESSE at PreNDA Meeting-CUV.AX		13/10/16	346.29KB	Share
CUV	FDA Schedules Pre-NDA Meeting for SCENESSE-CUV.AX	PRICE SENSITIVE	13/10/16	516.37KB	Share
CUV	AGM Date-CUV.AX		10/10/16	372.5KB	Share
CUV	Chair's Letter-CUV.AX		20/09/16	448.07KB	Share
CUV	Preliminary Final Report-CUV.AX	PRICE SENSITIVE	28/08/16	1.56MB	Share
CUV	Preliminary Final Report-CUV.AX	PRICE SENSITIVE	25/08/16	1.56MB	Share
CUV	Lapse and Forfeit of Unlisted Conditional Performance Rights-CUV.AX		23/08/16	424.26KB	Share
CUV	Clinuvel Newsletter-CUV.AX		16/08/16	604.62KB	Share
CUV	Becoming a substantial holder-CUV.AX		10/08/16	510.54KB	Share
CUV	Becoming a substantial holder-CUV.AX		10/08/16	180.11KB	Share
CUV	Change of Director's Interest Notice x 4-CUV.AX		05/08/16	1.09MB	Share
CUV	Appendix 3B-CUV.AX		04/08/16	628.27KB	Share
CUV	Clinuvel completes combination therapy pre-clinical study-CUV.AX	PRICE SENSITIVE	03/08/16	546.41KB	Share
CUV	Appendix 4C - quarterly-CUV.AX	PRICE SENSITIVE	29/07/16	172.78KB	Share
CUV	FDA accept SCENESSE clinical data package for NDA submission-CUV.AX	PRICE SENSITIVE	18/07/16	590.61KB	Share
CUV	FDA awards SCENESSE Fast Track designation for EPP treatment-CUV.AX	PRICE SENSITIVE	06/07/16	98.3KB	Share
CUV	SCENESSE launched in Europe-CUV.AX	PRICE SENSITIVE	22/06/16	542.37KB	Share
CUV	Clinuvel joins Nasdaq international Designation-CUV.AX		02/06/16	539.1KB	Share
CUV	SCENESSE Treatment in Europe-CUV.AX	PRICE SENSITIVE	18/05/16	544.47KB	Share
CUV	Appendix 4C - quarterly-CUV.AX	PRICE SENSITIVE	29/04/16	172.56KB	Share
CUV	Change in substantial holding-CUV.AX		11/04/16	1.1MB	Share
CUV	Clinuvel Newsletter-CUV.AX		05/04/16	674.63KB	Share
CUV	NICE Highly Specialised Technology workshop reviews SCENESSE		24/03/16	556.78KB	Share
CUV	s.708A Notice		18/03/16	63.72KB	Share
CUV	Appendix 3B		18/03/16	640.64KB	Share
CUV	Change in substantial holding		18/03/16	35.93KB	Share
CUV	Change in substantial holding		15/03/16	1.05MB	Share
CUV	Clinuvel accredits first European EPP expert centres	PRICE SENSITIVE	15/03/16	447.44KB	Share
CUV	Clinuvel Placement	PRICE SENSITIVE	15/03/16	448.22KB	Share
CUV	Trading Halt	PRICE SENSITIVE	11/03/16	469.04KB	Share
CUV	Appendix 4D and Half Year Report	PRICE SENSITIVE	19/02/16	304.86KB	Share
CUV	Clinuvel brief on European commercialisation	PRICE SENSITIVE	16/02/16	98.55KB	Share
CUV	US FDA orphan designation received for cutaneous porphyrias	PRICE SENSITIVE	12/02/16	115.51KB	Share
CUV	Presentation to international porphyria patient group		08/02/16	1.74MB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/16	172.15KB	Share
CUV	Change in substantial holding		25/01/16	1.25MB	Share
CUV	CEO Brief		20/01/16	270.13KB	Share
CUV	Change in substantial holding		18/01/16	246.56KB	Share
CUV	Update on North American vitiligo program for SCENESSE	PRICE SENSITIVE	03/12/15	132.79KB	Share

CUV CLINUVEL Regulatory Update
14/05/18	PRICE SENSITIVE	97.21KB	Share
CUV CLINUVEL TO TAKE 100% OWNERSHIP OF VALLAURIX JOINT VENTURE
01/05/18	PRICE SENSITIVE	558.83KB	Share
CUV Change in substantial holding
01/05/18		516.26KB	Share
CUV Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	794.86KB	Share
CUV CLINUVEL Newsletter
28/03/18		653.85KB	Share
CUV CLINUVEL hosts European EPP Expert Meeting
19/03/18	PRICE SENSITIVE	454.21KB	Share
CUV CLINUVEL sustains profitability first-half of year
28/02/18		449.58KB	Share
CUV Appendix 4D Half Yearly Report
28/02/18	PRICE SENSITIVE	476.86KB	Share
CUV CLINUVEL unveils new global positioning
20/02/18		711.49KB	Share
CUV CLINUVEL Newsletter
13/02/18		577.5KB	Share
CUV Initial Director's Interest Notice
31/01/18		338.87KB	Share
CUV Appendix 4C - quarterly
31/01/18	PRICE SENSITIVE	938.05KB	Share
CUV CLINUVEL appoints US-based Director
29/01/18		359.71KB	Share
CUV Chair Letter to Shareholders
11/01/18		357.85KB	Share
CUV CLINUVEL Newsletter
21/12/17		552.75KB	Share
CUV Preliminary assessment received from NICE
21/12/17	PRICE SENSITIVE	446.69KB	Share
CUV CLINUVEL Newsletter
07/12/17		568.35KB	Share
CUV Lapse and Forfeit of Unlisted Conditional Performance Rights
05/12/17		431.24KB	Share
CUV Final Director's Interest Notice
05/12/17		338.24KB	Share
CUV Results of Meeting
28/11/17		155.5KB	Share
CUV Managing Director AGM Presentation
28/11/17		2.81MB	Share
CUV Chairman's Address to Shareholders
28/11/17		508.55KB	Share
CUV Response to ASX Price Query
07/11/17	PRICE SENSITIVE	1.02MB	Share
CUV Appendix 4C - quarterly
30/10/17	PRICE SENSITIVE	953.72KB	Share
CUV Appendix 4G and Corporate Governance Statement
27/10/17		1.05MB	Share
CUV Annual Report to shareholders
27/10/17		1.66MB	Share
CUV Notice of Annual General Meeting/Proxy Form
27/10/17		501.21KB	Share
CUV CLINUVEL Newsletter
17/10/17		656.87KB	Share
CUV AGM Date
10/10/17		425.27KB	Share
CUV Non-Executive Director Retirement
04/10/17		432.4KB	Share
CUV CLINUVEL provides update on SCENESSE FDA filing
19/09/17	PRICE SENSITIVE	553.42KB	Share
CUV Appendix 3B
06/09/17		628.64KB	Share
CUV Preliminary Final Report
30/08/17	PRICE SENSITIVE	1.01MB	Share
CUV Change in substantial holding (Lagoda Investment Management)
09/08/17		2.07MB	Share
CUV Amended Appendix 4C - quarterly
31/07/17	PRICE SENSITIVE	931.69KB	Share
CUV Appendix 4C - quarterly
31/07/17	PRICE SENSITIVE	929.88KB	Share
CUV CLINUVEL Newsletter
25/07/17		477.75KB	Share
CUV Appendix 3B
10/05/17		628.38KB	Share
CUV CLINUVEL Newsletter
10/05/17		573.79KB	Share
CUV NICE England Update on SCENESSE
02/05/17	PRICE SENSITIVE	544.1KB	Share
CUV Appendix 4C - quarterly
28/04/17	PRICE SENSITIVE	808.16KB	Share
CUV Lapse and Forfeit of Unlisted Conditional Performance Rights
12/04/17		425.01KB	Share
CUV CLINUVEL reaches agreement on German SCENESSE pricing
12/04/17	PRICE SENSITIVE	563.42KB	Share
CUV Appendix 4D Half Yearly Report
24/02/17	PRICE SENSITIVE	479.08KB	Share
CUV CLINUVEL Newsletter
16/02/17		500.41KB	Share
CUV Appendix 4C - quarterly
31/01/17	PRICE SENSITIVE	341.5KB	Share
CUV Change of Director's Interest Notice
23/12/16		669.31KB	Share
CUV CLINUVEL Newsletter
20/12/16		771.68KB	Share
CUV Change of Director's Interest Notice
13/12/16		669.06KB	Share
CUV Results of Meeting
28/11/16		100.4KB	Share
CUV Managing Director AGM Presentation
28/11/16		1.82MB	Share
CUV Chairman's Address to Shareholders
28/11/16		97.65KB	Share
CUV CLINUVEL agrees with FDA on New Drug Application timelines
09/11/16	PRICE SENSITIVE	538.02KB	Share
CUV Response to ASX Price Query-CUV.AX
31/10/16	PRICE SENSITIVE	1002.55KB	Share
CUV Appendix 4C - quarterly-CUV.AX
31/10/16	PRICE SENSITIVE	343.77KB	Share
CUV Annual Report to shareholders-CUV.AX
27/10/16		1.44MB	Share
CUV Appendix 4G and Corporate Governance Statement-CUV.AX
27/10/16		1011.26KB	Share
CUV Notice of Annual General Meeting/Proxy Form-CUV.AX
27/10/16		453.62KB	Share
CUV CLINUVEL Relocates Melbourne Office-CUV.AX
24/10/16		328.66KB	Share
CUV FDA erythropoietic protoporphyria (EPP) scientific workshop-CUV.AX
24/10/16		336.8KB	Share
CUV SCENESSE - NICE England Update-CUV.AX
18/10/16	PRICE SENSITIVE	284.96KB	Share
CUV Media Release-CLINUVEL to discuss SCENESSE at PreNDA Meeting-CUV.AX
13/10/16		346.29KB	Share
CUV FDA Schedules Pre-NDA Meeting for SCENESSE-CUV.AX
13/10/16	PRICE SENSITIVE	516.37KB	Share
CUV AGM Date-CUV.AX
10/10/16		372.5KB	Share
CUV Chair's Letter-CUV.AX
20/09/16		448.07KB	Share
CUV Preliminary Final Report-CUV.AX
28/08/16	PRICE SENSITIVE	1.56MB	Share
CUV Preliminary Final Report-CUV.AX
25/08/16	PRICE SENSITIVE	1.56MB	Share
CUV Lapse and Forfeit of Unlisted Conditional Performance Rights-CUV.AX
23/08/16		424.26KB	Share
CUV Clinuvel Newsletter-CUV.AX
16/08/16		604.62KB	Share
CUV Becoming a substantial holder-CUV.AX
10/08/16		510.54KB	Share
CUV Becoming a substantial holder-CUV.AX
10/08/16		180.11KB	Share
CUV Change of Director's Interest Notice x 4-CUV.AX
05/08/16		1.09MB	Share
CUV Appendix 3B-CUV.AX
04/08/16		628.27KB	Share
CUV Clinuvel completes combination therapy pre-clinical study-CUV.AX
03/08/16	PRICE SENSITIVE	546.41KB	Share
CUV Appendix 4C - quarterly-CUV.AX
29/07/16	PRICE SENSITIVE	172.78KB	Share
CUV FDA accept SCENESSE clinical data package for NDA submission-CUV.AX
18/07/16	PRICE SENSITIVE	590.61KB	Share
CUV FDA awards SCENESSE Fast Track designation for EPP treatment-CUV.AX
06/07/16	PRICE SENSITIVE	98.3KB	Share
CUV SCENESSE launched in Europe-CUV.AX
22/06/16	PRICE SENSITIVE	542.37KB	Share
CUV Clinuvel joins Nasdaq international Designation-CUV.AX
02/06/16		539.1KB	Share
CUV SCENESSE Treatment in Europe-CUV.AX
18/05/16	PRICE SENSITIVE	544.47KB	Share
CUV Appendix 4C - quarterly-CUV.AX
29/04/16	PRICE SENSITIVE	172.56KB	Share
CUV Change in substantial holding-CUV.AX
11/04/16		1.1MB	Share
CUV Clinuvel Newsletter-CUV.AX
05/04/16		674.63KB	Share
CUV NICE Highly Specialised Technology workshop reviews SCENESSE
24/03/16		556.78KB	Share
CUV s.708A Notice
18/03/16		63.72KB	Share
CUV Appendix 3B
18/03/16		640.64KB	Share
CUV Change in substantial holding
18/03/16		35.93KB	Share
CUV Change in substantial holding
15/03/16		1.05MB	Share
CUV Clinuvel accredits first European EPP expert centres
15/03/16	PRICE SENSITIVE	447.44KB	Share
CUV Clinuvel Placement
15/03/16	PRICE SENSITIVE	448.22KB	Share
CUV Trading Halt
11/03/16	PRICE SENSITIVE	469.04KB	Share
CUV Appendix 4D and Half Year Report
19/02/16	PRICE SENSITIVE	304.86KB	Share
CUV Clinuvel brief on European commercialisation
16/02/16	PRICE SENSITIVE	98.55KB	Share
CUV US FDA orphan designation received for cutaneous porphyrias
12/02/16	PRICE SENSITIVE	115.51KB	Share
CUV Presentation to international porphyria patient group
08/02/16		1.74MB	Share
CUV Appendix 4C - quarterly
28/01/16	PRICE SENSITIVE	172.15KB	Share
CUV Change in substantial holding
25/01/16		1.25MB	Share
CUV CEO Brief
20/01/16		270.13KB	Share
CUV Change in substantial holding
18/01/16		246.56KB	Share
CUV Update on North American vitiligo program for SCENESSE
03/12/15	PRICE SENSITIVE	132.79KB	Share

REFRESH

First 4 5 6 7 8

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.22		Change 0.020(0.16%)		Mkt cap ! $612.5M

Open	High	Low	Value	Volume
$12.14	$12.36	$12.10	$558.7K	45.71K

Buyers (Bids)

No.	Vol.	Price($)
1	50	$12.15

Sellers (Offers)

Price($)	Vol.	No.
$12.37	433	1

View Market Depth

No.	Vol.	Price($)
1	100	12.140
2	2282	12.050
4	1401	12.000
2	3674	11.970
3	924	11.900

Price($)	Vol.	No.
12.370	433	1
12.440	800	1
12.450	100	1
12.750	48	1
12.800	600	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories